From Prototype to Profit: Commercialization Insights

A tiny $125k capital raise seems insignificant, but for Petro-Victory, it’s a key piece of a larger, sophisticated strategy to unlock value in Brazil.

Precision Aerospace & Defense is going public via a SPAC deal, unlocking capital to consolidate a fragmented A&D supply chain and expand its reach.

Amneal secures FDA approval for its generic Restasis, targeting a $2B market. But can its manufacturing strategy overcome late entry and quality concerns?

MAIA Biotechnology's CEO and directors bought over 182,000 shares, betting on their lung cancer drug with impressive Phase 2 results. Is this the signal?

Medtech firm Kestra Medical seeks new capital to scale its wearable defibrillator, signaling a major push in the competitive cardiovascular tech market.

A wealth manager's regulatory filing reveals its strategic play in the Empiric Student Property takeover, offering a rare look at M&A endgame tactics.

With FDA Breakthrough status, Ionis's olezarsen could transform care for millions with a dangerous lipid disorder by preventing life-threatening pancreatitis.

DÉKUPLE defies a cautious market with 12.7% growth, fueled by a strategic acquisition spree and a deep pivot to AI-driven digital marketing.

Virtualware’s strategic board appointments are more than a governance move; they're a blueprint for scaling in the booming enterprise immersive tech market.

The Estonian manufacturer shows Q3 operational gains, but ballooning debt and a costly real estate gamble raise questions about its long-term stability.

Federal Signal's acquisition of New Way Trucks isn't just a buyout; it's a calculated move into the resilient refuse market. Here's how it works.

Following pressure from activist Engine Capital, Civeo adds two new directors. Can they steer the hospitality giant toward renewed growth and profit?

As Core & Main preps its Q3 results, investors seek clues on infrastructure spending, market health, and if the firm can navigate economic crosswinds.

Artesa Build & Design expands from Texas to Miami, testing if its proven model can capture a slice of the competitive, high-end South Florida market.

ICARO Media Group is putting 50,000 AI-powered screens in Otis elevators. Is this the future of advertising or a privacy concern in plain sight?

Keurig Dr Pepper hires a new CFO with a history of major deals, signaling a critical phase in its plan to acquire JDE Peet's and split in two.

Kymera Therapeutics starts a pivotal Phase 2b trial for its oral eczema pill, a 'protein degrader' aiming to disrupt the multi-billion dollar injectable market.

With cash dwindling and Nasdaq warnings, Profusa bets its future on late-breaking clinical data for its revolutionary tissue-monitoring implant.

As Genmab's CFO prepares for a key fireside chat, investors are watching closely. Will its strategic bets on M&A and pipeline assets pay off?

Facing liquidation, Poxel SA unveils a complex recovery plan. Can it save its promising pipeline, or will the steep price of salvation be too high for investors?